vs

Side-by-side financial comparison of MFA FINANCIAL, INC. (MFA) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

MFA FINANCIAL, INC. is the larger business by last-quarter revenue ($55.5M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 9.2%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 7.7%).

MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MFA vs RXRX — Head-to-Head

Bigger by revenue
MFA
MFA
1.6× larger
MFA
$55.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+672.5% gap
RXRX
681.7%
9.2%
MFA
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
7.7%
MFA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MFA
MFA
RXRX
RXRX
Revenue
$55.5M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
97.9%
-304.8%
Net Margin
-304.2%
Revenue YoY
9.2%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.43
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MFA
MFA
RXRX
RXRX
Q4 25
$55.5M
$35.5M
Q3 25
$56.8M
$5.2M
Q2 25
$61.3M
$19.2M
Q1 25
$57.5M
$14.7M
Q4 24
$50.8M
$4.5M
Q3 24
$50.6M
$26.1M
Q2 24
$53.5M
$14.4M
Q1 24
$47.8M
$13.8M
Net Profit
MFA
MFA
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$48.1M
$-162.3M
Q2 25
$33.2M
$-171.9M
Q1 25
$41.2M
$-202.5M
Q4 24
$-178.9M
Q3 24
$48.2M
$-95.8M
Q2 24
$41.9M
$-97.5M
Q1 24
$23.2M
$-91.4M
Gross Margin
MFA
MFA
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
MFA
MFA
RXRX
RXRX
Q4 25
97.9%
-304.8%
Q3 25
84.5%
-3327.6%
Q2 25
54.5%
-916.8%
Q1 25
70.0%
-1297.9%
Q4 24
6.8%
-4042.4%
Q3 24
98.2%
-377.1%
Q2 24
79.1%
-697.4%
Q1 24
50.7%
-698.4%
Net Margin
MFA
MFA
RXRX
RXRX
Q4 25
-304.2%
Q3 25
84.7%
-3135.3%
Q2 25
54.2%
-894.2%
Q1 25
71.6%
-1373.3%
Q4 24
-3935.5%
Q3 24
95.2%
-367.5%
Q2 24
78.4%
-676.6%
Q1 24
48.5%
-662.4%
EPS (diluted)
MFA
MFA
RXRX
RXRX
Q4 25
$0.43
$-0.17
Q3 25
$0.35
$-0.36
Q2 25
$0.21
$-0.41
Q1 25
$0.31
$-0.50
Q4 24
$-0.01
$-0.56
Q3 24
$0.37
$-0.34
Q2 24
$0.32
$-0.40
Q1 24
$0.14
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MFA
MFA
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$213.2M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$1.8B
$1.1B
Total Assets
$13.0B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MFA
MFA
RXRX
RXRX
Q4 25
$213.2M
$743.3M
Q3 25
$305.2M
$659.8M
Q2 25
$275.7M
$525.1M
Q1 25
$253.7M
$500.5M
Q4 24
$338.9M
$594.4M
Q3 24
$305.6M
$427.6M
Q2 24
$289.4M
$474.3M
Q1 24
$306.3M
$296.3M
Total Debt
MFA
MFA
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MFA
MFA
RXRX
RXRX
Q4 25
$1.8B
$1.1B
Q3 25
$1.8B
$1.0B
Q2 25
$1.8B
$919.1M
Q1 25
$1.8B
$933.9M
Q4 24
$1.8B
$1.0B
Q3 24
$1.9B
$524.6M
Q2 24
$1.9B
$584.4M
Q1 24
$1.9B
$401.2M
Total Assets
MFA
MFA
RXRX
RXRX
Q4 25
$13.0B
$1.5B
Q3 25
$12.1B
$1.4B
Q2 25
$11.7B
$1.3B
Q1 25
$11.5B
$1.3B
Q4 24
$11.4B
$1.4B
Q3 24
$11.2B
$726.5M
Q2 24
$11.1B
$775.9M
Q1 24
$10.9B
$557.8M
Debt / Equity
MFA
MFA
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MFA
MFA
RXRX
RXRX
Operating Cash FlowLast quarter
$76.2M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MFA
MFA
RXRX
RXRX
Q4 25
$76.2M
$-46.1M
Q3 25
$14.7M
$-117.4M
Q2 25
$38.5M
$-76.4M
Q1 25
$-14.6M
$-132.0M
Q4 24
$200.1M
$-115.4M
Q3 24
$-11.3M
$-59.2M
Q2 24
$46.5M
$-82.2M
Q1 24
$53.5M
$-102.3M
Free Cash Flow
MFA
MFA
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
MFA
MFA
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
MFA
MFA
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
MFA
MFA
RXRX
RXRX
Q4 25
Q3 25
0.31×
Q2 25
1.16×
Q1 25
-0.35×
Q4 24
Q3 24
-0.23×
Q2 24
1.11×
Q1 24
2.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons